The FDA on December 15, 2025, approved ENHERTU® in combination with Pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test. ENHERTU® is a product of Daiichi Sankyo, Inc.
Bottom Ad
Advertisement
Subscribe
